Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 1,738 trials

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Rod Cone Dystrophy: SPVN06 Gene Therapy

We are evaluating the safety and tolerability of a new gene therapy for patients with rod cone dystrophy. This study aims to understand how well the treatment is tolerated in this specific group.

Hereditary Retinal Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Colorectal Cancer: UNICORN Study on Targeted Preoperative Treatments

We are studying short-course targeted treatments for patients with resectable colorectal cancer to see if they improve treatment response and quality of life. This trial aims to understand the safety and effectiveness of these treatments before surgery.

Colorectal Adenocarcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Preventing Second Cancers: Dostarlimab Study

We are studying whether dostarlimab can help prevent second primary cancers in patients who have been cured of their first cancer. This trial will also look at the safety of the treatment.

Cancer Survivor at Risk for Second Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Rituximab for Progressive Interstitial Lung Disease

We are studying whether rituximab can improve lung function in patients with progressive interstitial lung disease. This trial compares its effects to a placebo to assess safety and quality of life.

Interstitial Lung Disease>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Cognitive Deficits in Multiple Sclerosis: MODAFIMS Study

We are studying the effects of modafinil on cognitive deficits in people with Multiple Sclerosis. The trial aims to identify brain features that may predict treatment response and assess changes in cognitive function and quality of life.

Multiple Sclerosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesNeurology

NonAdvanced Systemic Mastocytosis: Bezuclastinib Study

We are testing a new oral medication, bezuclastinib, to see if it is effective and safe for patients with NonAdvanced Systemic Mastocytosis. This study compares the medication to a placebo to understand its potential benefits.

Systemic Mastocytosis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyHematology

Advanced Non-Small Cell Lung Cancer: Fianlimab and Cemiplimab Study

We are studying whether a combination of Fianlimab and Cemiplimab is more effective than Cemiplimab alone for adults with advanced non-small cell lung cancer. This trial focuses on patients whose tumors express PD-L1 at high levels.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)Standard MedicinesPartially RemoteOncology

HER2-positive Breast Cancer: Trastuzumab Deruxtecan Study

We are comparing a new treatment with standard therapy for patients with HER2-positive breast cancer. The goal is to see which approach leads to better outcomes and to understand the effects on quality of life.

HER2 Positive Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Triple-Negative Breast Cancer: PLX038 Treatment Study

We are studying the effects of PLX038 in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to see how well it works and to understand its safety and tolerability.

Advanced Triple-Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Prostate Cancer: Surgery with Darolutamide

We are studying whether adding darolutamide before and after surgery helps improve survival and quality of life for patients with high-risk or locally advanced prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Pneumococcal Vaccine Response in Lymph Nodes

We are studying how the immune system reacts to the pneumococcal vaccine by analyzing lymph nodes. This research may help us understand the timing and types of immune cells involved in the vaccine response.

Healthy VolunteersEfficacy phase (II)No PlaceboInvestigational MedicinesAllergologyInfectious Diseases

Breast Cancer: Ribociclib with Hormone Therapy and Radiotherapy

We are studying the safety and effectiveness of Ribociclib combined with hormone therapy and radiotherapy for elderly patients with hormone-positive, HER2-negative breast cancer. This trial is for those newly diagnosed who are not ready for surgery.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

High-Risk Prostate Cancer: THUNDER Trial

We are studying new diagnostic tracers and treatment options for men with high-risk prostate cancer. The goal is to see if these methods improve survival and quality of life compared to standard treatments.

Prostate Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesOncologyUrology

Richter Syndrome: GLOfitamab with Chemotherapy

We are studying a new treatment combining GLOfitamab with standard chemotherapy for patients with Richter syndrome. The goal is to see if this combination improves treatment response and safety.

Richter's Syndrome1-2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHematologyOncology

Triple-Negative Breast Cancer: Tiragolumab and Atezolizumab with Chemotherapy

We are studying a combination of two immunotherapy drugs with chemotherapy for patients with triple-negative breast cancer. This trial aims to evaluate the treatment's effectiveness and safety in both early and advanced stages of the disease.

Triple Negative Breast Cancer>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology